The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

<p>Muscle invasive bladder cancer (MIBC) has a poor prognosis. Currently, therapy consists of radical radiotherapy or cystectomy with or without chemotherapy. The average age of patients with MIBC is high and older patients are less able to tolerate surgery or chemoradiation due to their impai...

Detaylı Bibliyografya
Yazar:	Groselj, B
Diğer Yazarlar:	Kiltie, A
Materyal Türü:	Tez
Dil:	English
Baskı/Yayın Bilgisi:	2014
Konular:	Oncology Biology

Benzer Materyaller

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
Yazar:: Jennifer Antrobus, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
Yazar:: Paillas, S, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Identification of novel strategies to radiosensitise tumour cells
Yazar:: Anbalagan, S
Baskı/Yayın Bilgisi: (2014)

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
Yazar:: Jan M Klein, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
Yazar:: Lourenço, J
Baskı/Yayın Bilgisi: (2024)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
Yazar:: Lin Xiao, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Yazar:: Sharma, N, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
Yazar:: Anne Catherine Harttrampf, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Yazar:: Tao Yan-Fang, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
Yazar:: Monica Phimmachanh, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

The HDAC Inhibitor Panobinostat Promotes Expression of Delta 133p53 Variants in TP53 Wild-type Bladder Cancer Cells
Yazar:: Groselj, B, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
Yazar:: AGM Mostofa, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
Yazar:: Masumeh Sanaei, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Yazar:: Martina Korfei, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
Yazar:: Madeleine S. Q. Kortenhorst, ve diğerleri
Baskı/Yayın Bilgisi: (2006-01-01)

Histone Deacetylases and their Inhibitors in Cancer Epigenetics
Yazar:: Kelly N. Hassell
Baskı/Yayın Bilgisi: (2019-11-01)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
Yazar:: Pietro Di Fazio, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Yazar:: Yukiko Hazama, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Yazar:: Guo Li, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
Yazar:: Farbod Shojaei, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A
Yazar:: Ruicai Gu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
Yazar:: Zopf Steffen, ve diğerleri
Baskı/Yayın Bilgisi: (2012-09-01)

Fluid-electrolyte homeostasis requires histone deacetylase function
Yazar:: Kelly A. Hyndman, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Characterisation of the histone acetyltransferase KAT7 as a novel target for radiosensitisation
Yazar:: Bittner, M
Baskı/Yayın Bilgisi: (2017)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
Yazar:: Fengyi Guo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
Yazar:: Bin Tu, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
Yazar:: Danqi Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
Yazar:: Liebes Leonard, ve diğerleri
Baskı/Yayın Bilgisi: (2007-10-01)

Histone deacetylase inhibitors in multiple myeloma
Yazar:: Sarah Deleu, ve diğerleri
Baskı/Yayın Bilgisi: (2009-06-01)

Clinical Toxicities of Histone Deacetylase Inhibitors
Yazar:: Richard L. Piekarz, ve diğerleri
Baskı/Yayın Bilgisi: (2010-08-01)

The application of histone deacetylases inhibitors in glioblastoma
Yazar:: Rui Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Antidepressant Actions of Histone Deacetylase Inhibitors
Yazar:: Haggarty, Stephen J., ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Medicinal chemistry of histone deacetylase inhibitors
Yazar:: Ružić Dušan, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
Yazar:: Felix Orben, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Dietary fibre manipulation as a potential endogenous mechanism of radiosensitisation in bladder cancer
Yazar:: Then, CK
Baskı/Yayın Bilgisi: (2022)